Clinical Trial Update: Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing BAT2306 with Cosentyx for plaque psoriasis has completed, with the update focusing on efficacy and safety outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• BAT2306
• Cosentyx (secukinumab)

Snippet

Sponsor: Bio-Thera Solutions | Conditions: Plaque Psoriasis | Phase 3 | Status: COMPLETED